In larger studies, different doses of taranabant have shown beneficial effects in patients with obesity, leading to weight loss, a reduction in waist circumference [221], and improvements in cardiometabolic risk factors (increase in HDL cholesterol, reduction in triglyceride levels, improvements in insulin sensitivity [222], reduction in HbA1c levels, or reduction in fasting plasma glucose) [223]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.